Immunovant

IPO

Enabling normal lives with autoimmune disease

Public · New York, United States · Founded 2018 · $585.0M raised

Headquarters
New York, New York
Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$585.0M
Last Round
$550.0M Growth EquityOct 2019
Rounds
2
Type
Public

About

Immunovant is a clinical-stage immunology company developing FcRn inhibitor therapies to reduce harmful IgG autoantibodies in autoimmune disease. Its two investigational antibodies, IMVT-1402 and batoclimab, target FcRn as subcutaneous injections with tailored dosing across indications including Graves' disease, myasthenia gravis, and other IgG-mediated conditions.

Summary

Immunovant is a Biotech company based in New York, United States, founded in 2018. It has raised $585.0M in total across 2 rounds, most recently a $550.0M Growth Equity round in Oct 2019.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

IPOApr 2020
$139.4M

Sign up to see all 3 rounds

Growth Equity through IPO — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Immunovant on Indexed.vc
<a href="https://indexed.vc/companies/immunovant"><img src="https://indexed.vc/api/badge/company/immunovant" alt="Immunovant on Indexed.vc" width="260" height="76" /></a>